Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06536439

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool

A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.

Experimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.

Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).

The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.

Recruiting

Interested in participating?

Request Info

Key information

About this study

BACKGROUND:

For patients diagnosed with localized kidney cancer, two main options exist to surgically remove the kidney tumor. During radical nephrectomy (RN), the entire kidney is removed. During partial nephrectomy (PN), only the tumor is resected, safeguarding the function of the remaining healthy kidney tissue. This last procedure is preferred, but not always technically feasible. To resect only the tumor, a balance has to be found in the clamping approach: clamping the blood supply to the kidney assures bloodless tumor resection, yet compromises the postoperative renal function due to the temporary ischemia. Tumor resection without clamping on the other hand, might lead to substantial blood loss. That is why "selective clamping" (SC) is proposed. In this approach, only those selective arteries are clamped that perfuse the zone including the tumor. The main drawback of this strategy is that it is often not clear which arteries should be clamped based on standard preoperative imaging, while misjudgment can lead to a high-risk surgery with excessive bleeding or prolonged ischemia time. Therefore, RN is currently recommended when PN is considered not feasible. Better prediction of individual kidney perfusion will allow to perform more frequently a PN and thus save healthier kidney tissue. Additionally, it is difficult for patients to assess their own individual oncological situation based on 2D CT images.

With this project, the investigators want to offer the surgeon an easy-to-use virtual planning tool that facilitates the decision-making process regarding the feasibility of PN and the corresponding optimal clamping strategy. This tool uses virtual 3D models based on CT scans, to visualize precise information on the different anatomical structures and perfusion zones. This may also improve patients' understanding of their own individual situation. The proposed new tool (DIPLANN-tool) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.

DESIGN:

A confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.

Experimental group: the use of the DIPLANN model + conventional CT imaging for preoperative planning and perioperative guidance.

Control group: the use of only conventional CT imaging for preoperative planning and perioperative guidance (= current standard of care).

METHODOLOGY:

Sample size calculation: 235 patients.

Patients will be randomized according to a 1:1 allocation ratio to either the experimental group (the DIPLANN-tool in combination with conventional CT imaging) or the control group (conventional CT imaging alone), using permuted block randomization with blocks of varying size.

Randomization will be stratified on the following variables:

  • Whether SC is deemed possible according to the DIPLANN-tool in combination with conventional CT imaging or on conventional CT imaging alone, as assessed by an independent surgeon (between inclusion and randomization) who will not be not involved in the RAPN surgical procedure (yes vs no).
  • Hospital where surgery is performed.
  • PADUA classification (low (<8) and intermediate (8-9) vs high-risk (>9)). In case of multiple masses, the mass with the highest individual PADUA classification will be used.

PRIMARY OBJECTIVE:

To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery and in whom SC is deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed between inclusion and randomization by an independent surgeon.

SECONDARY OBJECTIVES:

  • To assess if the DIPLANN-tool in combination with conventional CT imaging is superior to conventional CT imaging alone, with respect to planning and performing as planned a SC strategy during RAPN, in patients diagnosed with localized kidney cancer who are planned to undergo renal cancer surgery.
  • To compare the DIPLANN-tool in combination with conventional CT imaging to conventional CT imaging alone with respect to: patients' health, patients' insight, and surgeons' benefits.

ENDPOINTS:

The primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.

Extended listing of all outcome measures: see below.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 18 years or above
  • cT1-2 N0 M0 renal mass
  • planned to undergo RAPN
  • multiphase CT scan with arterial phase available
  • voluntary given and written informed consent
  • sufficient in at least one of the study languages: Dutch, English, French

For the primary objective, SC needs to be deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed by an independent surgeon (between inclusion and randomization) who will not be involved in the RAPN surgical procedure, in order to be included in the analysis set. On the DIPLANN tool, SC is deemed feasible if >= 90% tumor ischemia and <= 70% renal parenchyma ischemia can be achieved. If these criteria are met, but it is technically or anatomically not feasible according to the independent surgeon to perform SC, he can deviate from these criteria and thus claim SC is not deemed possible. The results for the total population (patients in which SC is deemed possible AND impossible pre-operatively by an independent surgeon) will also be analyzed as a secondary objective.

Exclusion criteria

  • > 3 ipsilateral renal masses
  • women who are pregnant or breastfeeding
  • previous renal surgery that is expected to complicate renal cancer surgery
  • cT ≥ 3
  • planned off-clamp resection
  • cognitive disorder which impedes with completing study questionnaires

Treatment and study plan

Pre-operative explanation of the procedure (DIPLANN + CT)

Device

Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

Pre-operative surgical planning (DIPLANN + CT)

Device

Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.

RAPN (DIPLANN + CT)

Procedure

Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.

Pre-operative explanation of the procedure (CT only)

Device

Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.

Pre-operative surgical planning (CT only)

Device

Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.

RAPN (CT only)

Procedure

Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.

Primary outcomes

  1. Selective clamping

    Time frame: During surgery

    Planning and performing as planned a selective clamping (SC) strategy (considered by the surgeon at the end of surgery, objectified pre- and postoperatively through online assessment on study website and controlled through video-analysis): planning SC and performing the planned SC strategy = positive outcome; planning SC and performing another SC strategy or full clamping (FC) = negative outcome; planning FC = negative outcome.

Secondary outcomes

  1. eGFR 6 months

    Time frame: 6 months postoperatively

    Change in eGFR at 6 months after surgery compared to eGFR preoperatively.

  2. Clamping strategy

    Time frame: During surgery

    Clamping strategy performed (selective clamping or full clamping).

  3. Hilar dissection time

    Time frame: During surgery

    Time to dissect hilum (minutes) as analyzed on postoperative surgical video analysis.

  4. Conversion to full clamp

    Time frame: During surgery

    Conversion from SC to FC.

Other outcomes

  1. Complications

    Time frame: 90 days postoperatively

    Intra-operative and 90-day postoperative complications.

  2. Estimated blood loss

    Time frame: During surgery

    Estimated blood loss during surgery (mL).

  3. Perfusion model validation

    Time frame: During surgery

    Concordance between 3D perfusion model and peroperative kidney surface perfusion as visualized by ICG as estimated by postoperative surgical video analysis.

  4. Low eGFR 6 months

    Time frame: 6 months postoperatively

    eGFR (CKD-EPI) <45 ml/min at 6 months after surgery.

  5. Postoperative eGFR

    Time frame: up to 12 months postoperatively

    Change in eGFR (CKD-EPI) after surgery at other time points up to 1 year (postoperative day 1, last measurement before discharge, postoperatively 1 month, 3 months, 12 months) compared to eGFR preoperatively.

  6. Ischemia time

    Time frame: During surgery

    Ischemia time during surgery (seconds).

  7. Positive surgical margin rate

    Time frame: Postoperatively on average 10 days after surgery

    Positive surgical margin (PSM), as analyzed on histopathological examination.

  8. Console time

    Time frame: During surgery

    Robotic console time of surgery (minutes).

  9. Hospital stay

    Time frame: From day of surgery to day of discharge from the hospital: number of days includes day of the surgery as the first day and day of discharge from the hospital as the final day (estimated at 3 days, longer if more complicated hospitalisation)

    Length of hospital stay after surgery (days).

  10. Patient quality of life

    Time frame: up to 12 months postoperatively

    Quality of life (according to the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire: higher score = worse quality of life) up until 1 year after surgery (preoperatively, postoperatively at 3 months, 6 months, 12 months).

  11. Anxiety 1

    Time frame: Preoperatively

    Preoperative anxiety for surgery questionnaire: Hospital Anxiety and Depression Scale (HADS): higher score = more anxiety.

  12. Anxiety 2

    Time frame: Preoperatively

    Preoperative anxiety for surgery questionnaire: Symptom Distress Thermometer (SDT): higher score = more anxiety.

  13. Patient knowledge

    Time frame: Preoperatively

    Preoperative patient knowledge questionnaire. Higher score = more knowledge.

  14. Kidney dissection time

    Time frame: During surgery

    Time to dissect kidney (minutes) as analyzed on postoperative surgical video analysis.

  15. Superselective clamping rate

    Time frame: During surgery

    Superselective clamping (yes/no) as analyzed on postoperative surgical video analysis.

  16. Ischemic renal parenchyma

    Time frame: During surgery

    Percent renal parenchyma rendered ischemic.

  17. Conversion rate

    Time frame: During surgery

    Conversion from partial to radical nephrectomy.

Study contacts

Contact information is provided by the study sponsor or research team.

Charles Van Praet, MD, PhD

CONTACT

[email protected]

+32 9 332 22 76

Joris Vangeneugden, MD

CONTACT

[email protected]

+32 9 332 22 76

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Collaborators

  • Stichting tegen Kanker
  • University Ghent

Registry information

Official study title

Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy

Acronym: PODRACING

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Aug 5, 2024
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.